Divarasib (GDC-6036) is an orally active, selective KRASG12C inhibitor with an IC50 of KRASG12C, occupies the switch II pocket, blocks GTP binding and SOS-mediated reactivation, and inhibits oncogenic KRAS signaling. Divarasib induces tumor shrinkage and robust tumor growth inhibition in KRASG12C-positive models and cancer cells. Divarasib can be used for the research of non-small cell lung cancer, colorectal adenocarcinoma, pancreatic ductal adenocarcinoma, and other KRASG12C-mutated solid tumors[1][2][3][4].
Molekulargewicht:
622.06
Reinheit:
99.31
CAS Nummer:
[2417987-45-0]
Formel:
C29H32ClF4N7O2
Target-Kategorie:
Ras
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
